Skip to main content
Figure 1 | BMC Ophthalmology

Figure 1

From: Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study

Figure 1

Change of BCVA after treatment of ranibizumab and bevacizumab for myopic choroidal neovascularization. Graph shows serial changes in best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution (logMAR)) from baseline to 12 months after treatment. There were significant improvements from baseline BCVA after treatment in both groups. No statistical differences of BCVA were observed at the same periods after treatment between two groups.

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us